Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function

Chronic Renal Failure News

Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function
Chronic Kidney FailureCKD - Chronic Kidney DiseaseChronic Kidney Disease
  • 📰 Medscape
  • ⏱ Reading Time:
  • 44 sec. here
  • 23 min. at publisher
  • 📊 Quality Score:
  • News: 94%
  • Publisher: 55%

A SELECT trial subanalysis showed that semaglutide works as well in people with CVD, overweight/obesity, and impaired kidney function as it does in those with normal kidney function.

Participants with impaired kidney function treated with semaglutide showed a 31% reduction in major adverse cardiovascular events and a 33% lower risk of MACE or death from any cause.

SELECT enrolled 17,604 adults with a body mass index of 27 kg/m² or higher and a history of CVD across 41 countries. Participants received once-weekly semaglutide or placebo ​. Median follow-up was 3.5 years.ratio of 30 to < 300​ mg/g,​ and 11% taking placebo had a UACR of 30 to < 300​ mg/g.) comprised the primary endpoint, and the treatment effect on combined MACE and death from any cause was also an endpoint.

In addition, semaglutide was associated with a 20% reduction in MACE in both those with normal albumin or with albuminuria at baseline, she reported. Commenting on the work, comoderator, Fiona Gribble, MBChB, DPhil, professor of endocrine physiology, University of Cambridge, UK, said:"I think the results showed very convincingly that semaglutide works very effectively in people with impaired kidney function as without."

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

Chronic Kidney Failure CKD - Chronic Kidney Disease Chronic Kidney Disease CKD CV Risk Cardiovascular Risk CV Risk Factors Cardiovascular Risk Factors Cardiovascular Risk Management Kidneys Body Mass Index BMI UK Site Content United Kingdom Site Content United Kingdom UK Europe European Cardiovascular Disease Cvd - Cardiovascular Disease Myocardial Infarction

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Ozempic vs Wegovy: The Risks And Side Effects of Semaglutide DrugsOzempic vs Wegovy: The Risks And Side Effects of Semaglutide DrugsThe Best in Science News and Amazing Breakthroughs
Read more »

Semaglutide Coverage Could Raise Medicare Costs by BillionsSemaglutide Coverage Could Raise Medicare Costs by BillionsMedicare's expanded coverage for semaglutide meant that around one in seven Medicare beneficiaries with a high BMI would be newly eligible for semaglutide treatment.
Read more »

Semaglutide: A Diet Drug Dilemma for Medicare With a $145 Billion Price TagSemaglutide: A Diet Drug Dilemma for Medicare With a $145 Billion Price TagScience, Space and Technology News 2024
Read more »

Preventing Heart Attacks: Scientists Discover New Health Benefits of SemaglutidePreventing Heart Attacks: Scientists Discover New Health Benefits of SemaglutideScience, Space and Technology News 2024
Read more »

Low-Dose Semaglutide: Effective Weight Loss With Fewer Side EffectsLow-Dose Semaglutide: Effective Weight Loss With Fewer Side EffectsScience, Space and Technology News 2024
Read more »

Semaglutide: Weight Loss Drug May Reduce Risk of DeathSemaglutide: Weight Loss Drug May Reduce Risk of DeathOverweight and obese people with heart disease were less likely to die during a trial if taking semaglutide, a recent study found.
Read more »



Render Time: 2025-02-14 23:29:09